Evidence map›Paper›PMID 40161759›Full record

ArticlebioRxiv : the preprint server for biology2025

Two-Stage CD8

Guoshuai Cao, Yifei Hu, Tony Pan, Erting Tang, Nick Asby, Thomas Althaus, Jun Wan, Peter A Riedell, Michael R Bishop, Justin P Kline and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Guoshuai CaoPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
Yifei HuPritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA.
Tony PanPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
Erting TangPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
Nick AsbyPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
Thomas AlthausThe David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL 60637, USA.
Jun WanDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0001-9286-6562
Peter A RiedellCommittee on Cancer Biology, University of Chicago, Chicago, IL 60637, USA.
Michael R BishopDepartment of Medicine, University of Chicago, Chicago, IL 60637, USA.
Justin P KlineCommittee on Immunology, University of Chicago, Chicago, IL 60637, USA.
Jun HuangPritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.

Funding

The Institute for Translational MedicineUL1TR002389 · NCATS · UNIVERSITY OF CHICAGO · PI Joshua J Jacobs, DAVID O MELTZER · 2017 to 2026
$71.6M
MEDICAL SCIENTIST TRAININGT32GM007281 · NIGMS · UNIVERSITY OF CHICAGO · PI CLARK, MARCUS RAMSAY · 1985 to 2022
$32.1M
MULTIDISCIPLINARY CARDIAC SCIENCEST32HL007381 · NHLBI · UNIVERSITY OF CHICAGO · PI JEANNE M DECARA, Yoav Gilad · 1985 to 2026
$12.5M
Multi-Disciplinary Training Grant in Cancer ResearchT32CA009594 · NCI · UNIVERSITY OF CHICAGO · PI KAY F MACLEOD, Scott A. Oakes · 1989 to 2026
$11.5M
Molecular mechanism of natural killer cell recognitionDP2AI144245 · NIAID · UNIVERSITY OF CHICAGO · PI HUANG, JUN · 2018 to 2022
$2.9M
NCATS NIH HHS UL1 TR002389NCI NIH HHS T32 CA009594NHLBI NIH HHS T32 HL007381NIAID NIH HHS DP2 AI144245NIGMS NIH HHS T32 GM007281
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has expanded therapeutic options for patients with diffuse large B-cell lymphoma (DLBCL). However, progress in improving clinical outcomes has been limited by an incomplete understanding of CAR T-cell differentiation in patients. To comprehensively investigate CAR T-cell differentiation in vivo, we performed single-cell, multimodal, and longitudinal analyses of CD28-costimulated CAR T cells from infusion product and peripheral blood (day 8-28) of patients with DLBCL who were successfully treated with axicabtagene ciloleucel. Here, we show that CD8

Indexed as

axicabtagene ciloleucelCAR T-cell differentiationCD28-costimulated CARchimeric antigen receptor (CAR)large B-cell lymphomatwo-stage differentiation

Identifiers

PMID40161759
PMCPMC11952315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.